CBCT Image-Guided System Market Report 2026-2032: Strategic Analysis of Cone Beam CT-Guided Radiotherapy Amid Precision Oncology Expansion
Radiation oncology departments worldwide confront a persistent clinical tension: delivering ablative radiation doses to tumors while sparing adjacent healthy tissue within millimeter tolerances. The margin for error in modern radiotherapy is vanishingly small—positional deviations of merely 3-5 millimeters can shift dose distribution sufficiently to compromise tumor control probability or escalate normal tissue complication rates. CBCT Image-Guided Systems, integrating cone beam computed tomography directly onto linear accelerator gantries, address this precision imperative by enabling three-dimensional volumetric verification of patient anatomy immediately before and during treatment delivery. How will the global CBCT Image-Guided System market size evolve through 2032 as adaptive radiotherapy workflows become standard of care and emerging markets invest in linear accelerator infrastructure? Which system architectures will capture disproportionate market share in the transition toward online adaptive radiation therapy? This comprehensive market research report synthesizes 2021-2025 historical performance with 2026-2032 projections, delivering granular analysis across system types, clinical applications, and competitive dynamics.
Global Leading Market Research Publisher QYResearch announces the release of its latest report “CBCT Image-Guided System – Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global CBCT Image-Guided System market, including market size, share, demand, industry development status, and forecasts for the next few years.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6456437/cbct-image-guided-system
Market Size Trajectory, Volume Metrics, and Capital Equipment Dynamics
The global market for CBCT Image-Guided System was estimated to be worth USD 465 million in 2025 and is projected to reach USD 643 million, growing at a CAGR of 5.3% from 2026 to 2032. In 2025, the global sales volume of CBCT Image-Guided System was approximately 610 units, with an average price of USD 762,000 per unit and an average industry gross margin of around 38%. The unit economics reflect the high-value capital equipment nature of this market: each system represents a multi-decade institutional investment decision, with procurement cycles typically spanning 12-18 months from tendering to clinical commissioning.
CBCT Image-Guided System generally refers to a radiation therapy image-guided system centered on Cone Beam CT (CBCT). In clinical practice, this system can rapidly acquire three-dimensional patient positioning and anatomical images before or during treatment, and register them with the planning CT images. This corrects patient setup errors, monitors organ or tumor motion in real time, and provides technical support for clinical workflows such as adaptive radiation therapy. It typically appears as an integrated imaging subsystem mounted on the gantry of treatment devices including linear accelerators and Gamma Knife systems. Structurally, it usually consists of an X-ray tube, a flat-panel detector, a rotating mount/gantry interface, an image acquisition and reconstruction workstation, registration and setup software, and a control console.
Several converging structural drivers underpin the market size forecast. First, the global linear accelerator installed base continues to expand and refresh. Approximately 3,200 new linear accelerators were installed globally in 2025 according to industry tracking data, with virtually all new installations in developed markets incorporating on-board CBCT capability as standard configuration. The replacement cycle for existing linacs—typically 10-12 years—is driving CBCT retrofits and upgrades on aging systems where original IGRT capability is limited to planar kV imaging. Elekta’s 2025 annual report highlighted that its CBCT-guided radiotherapy systems achieved 14% order growth, with the company’s Unity MR-Linac and Harmony linac platforms both incorporating advanced CBCT imaging as standard.
Second, the rapid adoption of stereotactic body radiation therapy (SBRT) and stereotactic radiosurgery (SRS) techniques—which deliver extremely high fractional doses requiring sub-millimeter setup accuracy—is mandating CBCT-based pretreatment verification. The American Society for Radiation Oncology’s 2025 clinical practice survey documented that 71% of US radiation oncology facilities now routinely perform CBCT imaging for SBRT treatments, up from 53% in 2020. This trend is global: Japan’s National Cancer Center reported in its 2025 radiotherapy census that CBCT-guided SBRT procedures increased 27% year-over-year.
Third, the transition toward online adaptive radiation therapy—where treatment plans are modified based on daily anatomical changes detected on CBCT imaging—is creating demand for advanced CBCT configurations with 4D capability, respiratory gating, and direct integration with treatment planning systems. High-end configurations are further integrated with 4D-CBCT, respiratory gating, six-degree-of-freedom couch synchronization, online registration, and automatic correction modules. Varian’s Ethos therapy system, which incorporates AI-driven CBCT-based online adaptive planning capable of generating new treatment plans within 15 minutes, achieved 82 system installations globally by end-2025 according to Siemens Healthineers’ annual report, representing a 52% increase from the prior year.
System Architecture Segmentation: Integration Paradigms and Technical Considerations
The CBCT Image-Guided System market segmentation by type into On-Board Integrated and External Adapted configurations reflects fundamentally distinct clinical workflows and procurement economics. On-board integrated systems, where the entire imaging chain—X-ray tube, flat-panel detector, and rotational mount—is directly integrated into the treatment device gantry, represent the dominant and fastest-growing architecture. Some solutions are onboard CBCT systems, where the entire imaging chain is directly integrated into the treatment device itself. This integration enables seamless clinical workflow where imaging, registration, couch correction, and treatment delivery occur within a single patient setup without requiring patient transfer between separate imaging and treatment devices.
External adapted CBCT systems, typically ceiling-mounted or floor-mounted configurations positioned adjacent to the treatment couch, serve as retrofit solutions for legacy linear accelerators lacking on-board imaging capability. While representing a declining share of new installations, the external adapted segment remains relevant in markets where capital constraints preclude full linac replacement and where extending the clinical utility of existing treatment machines is prioritized.
From a manufacturing paradigm perspective, CBCT system production exhibits characteristics of both discrete and process manufacturing. The precision machining, detector calibration, and software integration stages represent discrete manufacturing with unit-level quality verification requirements. The detector manufacturing process—particularly cesium iodide scintillator deposition onto amorphous silicon flat-panel arrays—exhibits process manufacturing characteristics where cleanroom environmental control and deposition parameter stability directly determine image quality performance. This hybrid manufacturing nature creates supply chain complexity: a single CBCT system integrates components from precision mechanical engineering, semiconductor fabrication, and radiation physics domains.
Application Dynamics: IGRT as Core Indication with Adaptive Therapy Growth
The application segmentation encompasses Image-Guided Radiation Therapy (IGRT), Intensity-Modulated Radiation Therapy (IMRT) Precision Positioning, Stereotactic Body Radiation Therapy (SBRT), Adaptive Radiation Therapy (ART), and Radiation Therapy Patient Setup Verification. IGRT remains the foundational application, with CBCT-based pretreatment position verification now considered standard of care across guideline-issuing bodies including ASTRO and ESTRO.
The SBRT application is experiencing the most rapid growth, driven by the technique’s expanding indications in oligometastatic disease and early-stage lung cancer. SBRT requires volumetric imaging with sub-millimeter registration accuracy to verify target positioning before high-dose delivery. CBCT’s ability to visualize both bony anatomy and soft tissue targets—particularly in lung, liver, and spine applications—makes it the preferred IGRT modality for SBRT workflows. The February 2026 publication of the NRG Oncology LU-004 trial results in the Journal of Clinical Oncology, demonstrating improved local control with daily CBCT-guided SBRT for early-stage non-small cell lung cancer, is expected to further strengthen clinical guideline recommendations for volumetric IGRT in thoracic SBRT.
Adaptive Radiation Therapy (ART) represents the highest-growth application segment, driven by the clinical recognition that anatomical changes occurring during multi-week treatment courses can meaningfully impact dose delivery. The CBCT-based online adaptive workflow—where daily CBCT images are used to recalculate dose distributions and modify treatment plans while the patient remains on the treatment couch—represents the most sophisticated integration of imaging and therapy delivery.
Technology Challenges: Imaging Dose and Soft Tissue Contrast
Persistent technical challenges in CBCT-guided radiotherapy warrant analytical attention. Imaging dose accumulation represents a significant concern: daily CBCT acquisitions over a 30-35 fraction treatment course deliver cumulative imaging doses to normal tissues that are clinically meaningful for pediatric patients and young adults with curative cancer diagnoses. The January 2026 report from the American Association of Physicists in Medicine’s Task Group on CBCT Dose Optimization provided updated guidance recommending iterative reconstruction algorithms and reduced acquisition protocols that achieve diagnostic-quality images at 40-60% lower dose than conventional filtered back-projection techniques.
Soft tissue contrast remains inferior to diagnostic CT, limiting CBCT’s ability to visualize certain tumor types without contrast administration. Emerging technologies including dual-energy CBCT and deep learning-based image synthesis—where synthetic CT images with diagnostic-quality contrast are generated from CBCT acquisitions—represent active research frontiers. United Imaging’s February 2026 introduction of its DeepRecon CBCT image enhancement platform, utilizing a convolutional neural network trained on paired CBCT-diagnostic CT datasets, reportedly improves soft tissue contrast-to-noise ratio by approximately 45% compared to conventional reconstruction.
Competitive Landscape: Global Leaders and Regional Challengers
The CBCT Image-Guided System market competitive landscape is concentrated among integrated radiotherapy equipment manufacturers. Key market participants include Siemens Healthineers (Varian), Elekta, medPhoton, Neusoft Medical, Shanghai United Imaging Healthcare Co. Ltd., Hefei CAS Ion Medical Equipment Co. Ltd., and Our United Corporation.
Siemens Healthineers, through its Varian business acquired in 2021, maintains global market leadership with its TrueBeam and Halcyon platforms incorporating advanced CBCT capabilities. Varian’s 2025 annual report documented that its IGRT-enabled linac installed base exceeded 5,800 systems globally, providing a substantial recurring revenue base for CBCT software upgrades and service contracts. Elekta’s CBCT platform, integrated across its Versa HD and Harmony linac portfolios, emphasizes imaging quality and workflow efficiency. Shanghai United Imaging Healthcare, China’s leading radiotherapy equipment manufacturer, achieved significant domestic market share gains following its 2025 inclusion in multiple provincial-level hospital procurement programs. The company’s uRT-Linac platform with integrated CBCT capability has been installed in over 210 Chinese hospitals.
Strategic Outlook
The CBCT image-guided system market’s trajectory toward USD 643 million by 2032 at 5.3% CAGR reflects the central role of volumetric image guidance in modern radiation oncology practice. Strategic imperatives include: investing in AI-driven image reconstruction and registration algorithms that reduce acquisition time and imaging dose; developing 4D-CBCT and respiratory-correlated imaging capabilities for motion-managed treatments; and expanding CBCT integration into proton therapy gantries, where the higher sensitivity to anatomical changes creates an even more compelling clinical need for volumetric pretreatment verification.
Segment by Type
On-Board Integrated
External Adapted
Segment by Application
Image-Guided Radiation Therapy (IGRT)
Intensity-Modulated Radiation Therapy (IMRT) Precision Positioning
Stereotactic Body Radiation Therapy (SBRT)
Adaptive Radiation Therapy (ART)
Radiation Therapy Patient Setup Verification
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
E-mail: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
